Cargando…
BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway
Background: Bromodomain and extra-terminal domain (BET) inhibitors have shown profound efficacy against hematologic malignancies and solid tumors in preclinical studies. However, the underlying molecular mechanism in melanoma is not well understood. Here we identified secreted phosphoprotein 1 (SPP1...
Autores principales: | Deng, Guangtong, Zeng, Furong, Su, Juan, Zhao, Shuang, Hu, Rui, Zhu, Wu, Hu, Shuo, Chen, Xiang, Yin, Mingzhu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546000/ https://www.ncbi.nlm.nih.gov/pubmed/33052224 http://dx.doi.org/10.7150/thno.47432 |
Ejemplares similares
-
EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma
por: Deng, Guangtong, et al.
Publicado: (2022) -
BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression
por: Zeng, Furong, et al.
Publicado: (2023) -
Noncanonical NF-κB in Cancer
por: Tegowski, Matthew, et al.
Publicado: (2018) -
Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo
por: Falcinelli, Shane D., et al.
Publicado: (2022) -
Expanding the
Interactome of the Noncanonical NF-κB
Signaling Pathway
por: Willmann, Katharina L., et al.
Publicado: (2016)